Fig. 2: Serological inhibition of spike-ACE2 interaction and direct antibody binding to spike/RBD. | Nature Aging

Fig. 2: Serological inhibition of spike-ACE2 interaction and direct antibody binding to spike/RBD.

From: Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection

Fig. 2: Serological inhibition of spike-ACE2 interaction and direct antibody binding to spike/RBD.

a, Serological inhibition of spike binding to ACE2. Spike proteins were available from the viral variants Wuhan (purple), B1.1.7 (blue), B.1.351 (green) and P.1 (orange). Sera were obtained from donors after natural infection at baseline and then 2 and 4 months after the baseline sample. Tukey’s multiple comparisons test, ****P < 0.0001 (n = 163 individuals with 3 sample collections each were tested). b, Serological binding to SARS-CoV-2 spike from viral variants (Wuhan (purple), B1.1.7 (blue), B.1.351 (green) and P.1 (orange)) after natural infection at baseline. Tukey’s multiple comparisons test. NS, not significant (n = 163 individuals with 3 sample collections each were tested). c, Serological binding to SARS-CoV-2 RBD from viral variants (Wuhan (purple), B1.1.7 (blue), B1.351 (green) and P.1 (orange)) after natural infection at baseline. Tukey’s multiple comparisons test, ****P < 0.0001 (n = 163 individuals with 3 sample collections each were tested).

Back to article page